Invest in companies that ‘think twice’ about hiring during a Fed-mandated slowdown, Jim Cramer says

Invest in companies that ‘think twice’ about hiring during a Fed-mandated slowdown, Jim Cramer says


CNBC’s Jim Cramer on Wednesday advised investors to buy stock of companies that are adjusting their hiring efforts to fit the economic environment.

“If you want to invest with profligate companies, be my guest. I want to invest in well-run companies … with very smart CEOs. That means buying the stocks of those companies that think twice about continuing to hire in this environment,” he said.

The “Mad Money” host’s comments come after Google said in an email to employees that it will pause hiring for two weeks, according to The Information. Parent-company Alphabet said last week in a memo to employees that it plans to slow down the pace of hiring through next year, citing economic headwinds.

Shares of Alphabet closed slightly up on Wednesday.

“It is still ridiculous that anyone is freaking out over these stories, still. These stories about a hiring slowdown, as unfortunate as they are. … When you hear ‘Fed-mandated slowdown,’ that means less hiring and more layoffs,” he said.

The Federal Reserve has increased interest rates this year to tamp down skyrocketing inflation, sparking fears about a looming recession. The Fed’s next meeting will take place later this month, and investors expect a 75- or 100-basis point rate hike after June’s red-hot inflation numbers.

Cramer told investors that instead of nervously eying large companies and their hiring moves, they should focus on taking a long-term strategy for their portfolios.

“Take long-term positions in what you like or simply buy a very good index fund in terms of the low cost, and hold it. That’s been the best form of investing and it’s one that historically handily beats inflation,” he said.

Disclosure: Cramer’s Charitable Trust owns shares of Alphabet.



Source

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi
Business

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

Signage outside Johnson & Johnson offices in Irvine, California, US, on Friday, Oct. 10, 2025. Kyle Grillot | Bloomberg | Getty Images Johnson & Johnson on Wednesday said the U.S. Food and Drug Administration approved its once-daily psoriasis pill, the first oral option to rival best-selling shots. The FDA approved the pill, Icotyde, to treat […]

Read More
Macy’s store revamp shows progress, but company expects sales to fall this year
Business

Macy’s store revamp shows progress, but company expects sales to fall this year

Macy’s on Wednesday beat Wall Street’s quarterly sales and profit expectations as its namesake brand showed signs of progress, yet still gave a cautious outlook for the year ahead. For the fiscal year, the company – which includes its namesake chain, higher-end department store Bloomingdale’s and beauty retailer Bluemercury – said it expects sales of […]

Read More
Disney embarks on new chapter as Josh D’Amaro takes over as CEO
Business

Disney embarks on new chapter as Josh D’Amaro takes over as CEO

Larissa Manoela and Josh D’Amaro, Chairperson of Walt Disney Parks and Resorts, wave to the audience after Panel Disney Experiences during Day 2 of the D23 Brazil: A Disney Experience at Transamerica Expo Center on November 09, 2024 in Sao Paulo, Brazil. Ricardo Moreira | Getty Images Disney is turning the page on a new […]

Read More